4.6 Article

Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5)

期刊

BONE
卷 107, 期 -, 页码 161-171

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2017.11.012

关键词

Autosomal dominant; Bisphosphonates; Cemento-ossifying fibroma; Cherubism; Diaphyseal sclerosis; Fracture; Psammomatoid bodies

资金

  1. Shriners Hospitals for Children
  2. Clark and Mildred Cox Inherited Metabolic Bone Disease Research Fund at The Barnes-Jewish Hospital Foundation
  3. United States Agency for International Development
  4. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057235, F32AR008586, R01AR070030] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079656] Funding Source: NIH RePORTER
  6. Div Of Biological Infrastructure [1356569] Funding Source: National Science Foundation

向作者/读者索取更多资源

Gnathodiaphyseal dysplasia (GDD; OMIM#166260) is an ultra-rare autosomal dominant disorder caused by heterozygous mutation in the anoctamin 5 (ANO5) gene and features fibro-osseous lesions of the jawbones, bone fragility with recurrent fractures, and bowing/sclerosis of tubular bones. The physiologic role of ANO5 is unknown. We report a 5-year-old boy with a seemingly atypical and especially severe presentation of GDD and unique ANO5 mutation. Severe osteopenia was associated with prenatal femoral fractures, recurrent postnatal fractures, and progressive bilateral enlargement of his maxilla and mandible beginning at similar to 2 months-of-age that interfered with feeding and speech and required four debulking operations. Histopathological analysis revealed benign fibro-osseous lesions resembling cemento-ossifying fibromas of the jaw without psammomatoid bodies. A novel, de novo, heterozygous, missense mutation was identified in exon 15 of ANO5 (c.1553G>A; p.Gly518G1u). Our findings broaden the phenotypic and molecular spectra of GDD. Fractures early in life with progressive facial swelling are key features. We assessed his response to a total of 7 pamidronate infusions commencing at age 15 months. Additional reports must further elucidate the phenotype, explore any genotype phenotype correlation, and evaluate treatments. (C) 2017 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据